在固体瘤中增强CAR-T细胞透的障碍和策略:系统性审查
Yan Zhang1, Huihui Sun2, Lianfeng Zhao1
1Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China.
Immunology
|January 19, 2026
概括
化学抗原受体T (CAR-T) 细胞疗法对固体瘤有希望,但面临透障碍. 本综述详细介绍了这些挑战,并探讨了提高对固体瘤的CAR-T细胞治疗疗效的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 化学抗原受体T (CAR-T) 细胞疗法已经改变了血液恶性瘤治疗.
- 在固体瘤中CAR-T细胞的应用受到重大障碍的阻碍,主要是瘤透不良.
研究的目的:
- 系统地审查限制CAR-T细胞透到固体瘤中的因素.
- 突出生物工程和组合策略,以改善固体瘤中CAR-T细胞治疗.
主要方法:
- 对固体瘤微环境障碍的机制性见解.
- 对创新的生物工程方法的审查.
- 对CAR-T细胞治疗的组合策略的分析.
主要成果:
- 确定了关键的障碍:化学激素不匹配,血管系统异常,免疫抑制细胞,密集的肌层,T细胞功能障碍,代谢极限,瘤异质性和运输问题.
- 制定了克服这些透障碍的战略.
结论:
- 克服透障碍对于在固体瘤中推进CAR-T细胞治疗至关重要.
- 将机械学理解与生物工程和组合疗法的整合为提高疗效和耐用性提供了前进的途径.
相关概念视频
10:12Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers
2.8K
This protocol describes the synthesis of cyclic cell-penetrating peptides with aromatic cross-links and the evaluation of their permeability across biological...
2.8K
05:14Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
797
Given the limited xenograft models available to study interactions between human CART and myeloid cells, we established in vitro and in vivo models to understand the impacts of human macrophages on CART cells. Findings can potentially be generalized to evaluate macrophage roles in the tumor microenvironment and test macrophage-targeted...
797
06:22Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells
4.8K
This protocol streamlines retroviral vector production and murine T cell transduction, facilitating the efficient generation of mouse CAR-T...
4.8K
06:51Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
15.9K
We describe an approach to reliably generate chimeric antigen receptor (CAR) T cells and test their differentiation and function in vitro and in...
15.9K
07:56Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
11.8K
Here, we present a protocol to genetically edit CAR-T cells via a CRISPR/Cas9...
11.8K
06:33Production of Human CRISPR-Engineered CAR-T Cells
14.4K
Here, we present a protocol for gene editing in primary human T cells using CRISPR Cas Technology to modify CAR-T...
14.4K


